A new treatment targetted at one of the most common cancer killers in Chinese and Taiwanese people is to go on trial in Hong Kong, researchers said today. The treatment, developed in Australia, works by stimulating the immune system to "train" blood cells to attack and kill cancer cells in patients suffering from nose and throat cancer. Nasopharyngeal Carcinoma (NPC) - also known as Guangdong Cancer or Canton Cancer because of the high incidence of the disease among Chinese - is a virulent cancer of the nose and throat and one which is often difficult to treat effectively. It is one of the top four cancer killers in Guangdong region of China which borders Hong Kong and was formerly known as Canton. In Hong Kong, there are between 900 and 1,000 new cases every year compared to around 2,000 in the whole of the United States. -- SPA
